NovoCure Limited (NVCR) Company Profile
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night. The Company has performed various pre-clinical research on TTFields and their effects in multiple solid tumor cancers.
News about NVCR
The No BS Plan Report, Week 5: Does Sideways Movement Mean An Imminent Inflection Point?
Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Spoiler alert: Week 5 was fairly boring in terms of trad...Read More>>>
The No BS Plan, Week 4: Whoa!
Weeks 2 and 3 presented a sort of mixed bag, placing my personal pet holding Advaxis (ADXS) on notice and ultimately bowing out of one of the lots in the plan. So how is the plan faring? First, let's get to the recap of the rules, which are laid out ...Read More>>>
3 Things In Biotech, March 10: Merck In MS, Bayer's Essure Scrutinized, Tocagen An Orphan
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-movin...Read More>>>
Game Plan For The Week - Cramer's Mad Money (2/26/18)
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, February 26. Cramer is back with Mad Money. "Things have gotten a little crazy around here. That's why I think what we need, more than anything else at the moment,...Read More>>>
More Health Care Catalysts to Watch For by the End of February
Generally speaking, companies that reside within the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But consider that with t...Read More>>>